Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BYClinics (Sao Paulo, Brazil)

Prestin as a potential biomarker in peripheral blood: differential expression across hearing loss subtypes and acute inner ear injury.

  • Xuan Sun1
  • Dian Wang1
  • Yahan Zhao1
  • Zhenghan Zhu2
  • Lingxiang Hu3
  • Yi Li4
4 affiliations
  1. 1Beijing Tongren Hospital, Capital Medical University, China.
  2. 2The Second Affiliated Hospital of Nanjing Medical University, China.
  3. 3Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, China.
  4. 4Beijing Tongren Hospital, Capital Medical University, China. Electronic address: [email protected].
Read full textPDFDOICite

Abstract

Objective

This exploratory study investigated peripheral blood Prestin levels across different hearing loss subtypes to evaluate its potential as a biomarker for inner ear injury.Methods

Plasma Prestin levels were measured via ELISA in 100 age-matched participants, comprising a healthy control group (HCG, n = 23) and patients with conductive (CHLG, n = 29) and unilateral sudden sensorineural hearing loss (USSNHLG, n = 48). Associations with hearing loss subtypes, initial audiogram configurations, and treatment outcomes were analyzed.Results

Overall, Prestin levels varied significantly across the three groups (P < 0.001). Following Dunn's test with Bonferroni correction, Prestin levels in the USSNHLG were significantly higher than those in the HCG (P = 0.019), whereas levels in the CHLG were significantly lower than those in the HCG (P = 0.014). Within the USSNHLG, no statistically significant differences in Prestin levels were observed among patients with different therapeutic outcomes (P = 0.102).Conclusions

The present findings confirm that acute inner ear injury (USSNHL) is associated with significantly elevated peripheral blood Prestin levels, whereas persistently reduced acoustic input (CHL) is associated with decreased levels. However, current data do not support baseline Prestin as a prognostic indicator for USSNHL. Future multicenter studies with strict clinical stratification are required to fully establish its clinical utility.

Related

  1. Neurodegenerative disease risk associated with gene expression in peripheral monocytes across ancestries
    Aaron Z. Wagen, Regina H. Reynolds, Jia Nee Foo +7
    Communications BiologyPeer-reviewedCC BY 4.0Full textGenetics & genomicsCrossref
  2. Paired Transcriptomics of Glioblastoma Peripheral and Core Areas Reveals CNTN2 as a Potential Therapeutic Target
    Mathieu Larroquette, Katharina Sarnow, Miriam Meloni +14
    Cancer LettersPeer-reviewedLicence not statedGeneral biologyEpidemiology & public healthHAL
  3. NicheCorr: Identifying Niche-Specific Differential Gene Co-Expression in Spatial Transcriptomics
    S. Yang, Y.-Y. Ho, D. Fan
    bioRxivPreprintAll rights reservedFull textGenetics & genomicsbioRxiv
  4. Differential Gene Expression and Functional Enrichment Analysis of Breast Tumor and Normal Tissue RNA-seq Data: A Reanalysis of GEO Dataset GSE210787
    N. Surisetty, B. Singh
    bioRxivPreprintAll rights reservedFull textBioinformatics & computational biologybioRxiv
  5. Differential Gene Expression in the Tropical House Cricket and Its Iridovirus in Healthy versus Diseased Specimens
    J. A. Hinton, H. K. Walt, K. R. Duffield +3
    bioRxivPreprintAll rights reservedFull textBioinformatics & computational biologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{sun2026prestin,
  title = {{Prestin as a potential biomarker in peripheral blood: differential expression across hearing loss subtypes and acute inner ear injury.}},
  author = {Xuan Sun and Dian Wang and Yahan Zhao and Zhenghan Zhu and Lingxiang Hu and Yi Li},
  journal = {Clinics (Sao Paulo, Brazil)},
  year = {2026},
  month = oct,
  doi = {10.1016/j.clinsp.2026.101143},
  url = {https://europepmc.org/article/MED/42880127},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Prestin as a potential biomarker in peripheral blood: differential expression across hearing loss subtypes and acute inner ear injury.
AU  - Xuan Sun
AU  - Dian Wang
AU  - Yahan Zhao
AU  - Zhenghan Zhu
AU  - Lingxiang Hu
AU  - Yi Li
PY  - 2026
DA  - 2026/10/15
JO  - Clinics (Sao Paulo, Brazil)
DO  - 10.1016/j.clinsp.2026.101143
UR  - https://europepmc.org/article/MED/42880127
AB  - Objective  This exploratory study investigated peripheral blood Prestin levels across different hearing loss subtypes to evaluate its potential as a biomarker for inner ear injury.Methods  Plasma Prestin levels were measured via ELISA in 100 age-matched participants, comprising a healthy control group (HCG, n = 23) and patients with conductive (CHLG, n = 29) and unilateral sudden sensorineural hearing loss (USSNHLG, n = 48). Associations with hearing loss subtypes, initial audiogram configurations, and treatment outcomes were analyzed.Results  Overall, Prestin levels varied significantly across the three groups (P < 0.001). Following Dunn's test with Bonferroni correction, Prestin levels in the USSNHLG were significantly higher than those in the HCG (P = 0.019), whereas levels in the CHLG were significantly lower than those in the HCG (P = 0.014). Within the USSNHLG, no statistically significant differences in Prestin levels were observed among patients with different therapeutic outcomes (P = 0.102).Conclusions  The present findings confirm that acute inner ear injury (USSNHL) is associated with significantly elevated peripheral blood Prestin levels, whereas persistently reduced acoustic input (CHL) is associated with decreased levels. However, current data do not support baseline Prestin as a prognostic indicator for USSNHL. Future multicenter studies with strict clinical stratification are required to fully establish its clinical utility.
SN  - 1807-5932
SN  - 1980-5322
ER  -